// App-Quantinova.ai

Tu2039 : Turquoise-II: Svr12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults With Compensated Cirrhosis Treated With ABT-450/r/ABT-267 and ABT-333 Plus Ribavirin (3D+RBV)

Researchers

Presenter

  • Fred Poordad

Principal Investigators

  • Roger Trinh

  • Sandra S. Lovell

  • Barbara DaSilva-Tillmann

  • Andrew L. Campbell

  • Thomas Podsadecki

  • Christophe Hezode

  • Stefan Zeuzem

  • Kosh Agarwal

  • Mitchell L. Shiffman

  • Heiner WEDEMEYER

  • Thomas Berg

  • Eric M. Yoshida

  • Xavier Forns

Medical Centers

  • Institute of Liver Studies, Kings CollegeHospital NHS Trust, London , United Kingdom

  • Liver Unit,, Hospital Clinic, IDIBAPS and CIBEREHD, Barcelona, Spain

  • Medizinische Hochschule Hannover, Hannover, Germany

  • Henri Mondor Hospital, APHP, University Paris-Est, Inserm U, Creteil, France

  • Liver Institute of Virginia, Newport News, VA

  • Goethe University, Frankfurt, Germany

  • The University of British Columbia, Vancouver, BC, Canada

  • The Texas Liver Institute/University of Texas Health Science Center, San Antonio, TX

  • Digestive Diseases and Cancer Institutes, Virginia Mason Medical Center, Seattle, WA

  • Universitaetsklinikum Leipzig, Leipzig, Germany

Locations

  • Canada

  • Spain

  • Germany

  • Uganda

  • United States

  • France

Companies

  • AbbVie Inc.

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Hepatitis C

  • Cirrhosis

Biomarkers

  • Human albumin

Drug/Treatment

  • Alfa-fetoprotein

  • Interferon

  • Ritonavir

  • Ribavirin

  • paritaprevir

  • ABT 333

Outcome

  • N/A

Study Design

  • open label

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved